E-Cigarettes vs. Nicotine Therapy to Stop Smoking

E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy according to this randomized study recently published in the New England Journal of Medicine (NEJM). Both must be accompanied by medical and psychological support for optimal results.

Enfermedad pulmonar y cigarrillos electrónicos: Nuevos dispositivos con nuevas enfermedadesWhile e-cigarettes are commonly used as a smoking cessation strategy, evidence is limited regarding their effectiveness as compared with other strategies such as approved nicotine products (chewing gum, candy, patches, etc.) that act as nicotine replacement to help patients stop smoking permanently.

 

A total of 886 participants attending dedicated U.K. stop-smoking services underwent randomization to either nicotine-replacement products (different combinations or presentations) for 3 months or an e-cigarette (a second-generation refillable e-cigarette with one bottle of nicotine e-liquid [18 mg/mL]). Flavor and strength were left to the patients’ choice. Treatment was to be followed for at least 4 weeks.


Read also: E-Cigarettes: No Definitive Evidence on Their Potential Cardiovascular Effect, but Some Suggest Caution.


For both treatment arms, treatment included counseling follow-up for at least 4 weeks.

 

The primary outcome was sustained abstinence for one year, which was validated biochemically at the final follow-up visit. Participants who were lost to follow-up or did not access biochemical validation were considered to not be abstinent.

 

The abstinence rate at one year was 18% in the e-cigarette group vs. 9.9% in the nicotine-replacement group (relative risk [RR]: 1.83; 95% confidence interval [CI]: 1.30 to 2.58; p < 0.001). While the abstinence rate for e-cigarettes almost doubled the rate for nicotine-replacement therapy, 18% is still very low and we should insist so that more patients can quit smoking for good.


Read also: Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference.


The most frequently reported events were throat or mouth irritation for the e-cigarette group and nausea for the nicotine-replacement group.

 

Symptoms such as cough and phlegm production were also minor in the e-cigarette group.

 

There were no differences between groups in the incidence of bronchospasm or dyspnea.

 

Conclusion

E-cigarettes were more effective for smoking cessation than nicotine-replacement therapy when both were accompanied by psychological and medical advice.

 

Original title: A Randomized Trial of E-Cigarettes Versus Nicotine-Replacement Therapy.

Reference: Peter Hajek et al. N Engl J Med. 2019 Feb 14;380(7):629-637.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...